News
Press Releases
Press Releases
Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference   DURHAM, NC, September 24, 2024 – Atsena Therapeutics, a clinical-stage gene therapy company ...
Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis Marks second FDA designation for ATSN-201, which ...
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet First time patients with ...
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis  Priority Review Voucher would be issued ...
Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair
Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair Biotech and pharma veteran brings expertise in therapeutic development and commercialization   DURHAM, NC, July 15, ...
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS) ...
Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS) ...
Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1) Positive 12-month safety and efficacy data ...
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by ...
Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1 ATSN-101 has demonstrated clinically meaningful improvements in vision at ...
Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling male patients ages 6-64 with RS1-associated XLRS ATSN-201 leverages novel ...
Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis
ATSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate safe delivery of RS1 to photoreceptors in the central retina/fovea Initiation of ...
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post treatment Data presented at ARVO ...
Atsena Therapeutics Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101 to be Presented at ARVO 2023 Annual Meeting
DURHAM, NC, April 11, 2023 – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or ...
Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting
ATSN-101 has demonstrated clinically meaningful improvements in vision with no drug-related serious adverse events DURHAM, NC, February 8, 2023 – Atsena Therapeutics, a clinical-stage gene ...
Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
DURHAM, NC, December 7, 2022 – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or ...
Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
Biotech leader brings extensive experience in finance, business development and corporate strategy DURHAM, NC, November 7, 2022 – Atsena Therapeutics, a clinical-stage gene therapy company ...
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
ATSN-101 demonstrated clinically meaningful improvements in vision with no drug-related serious adverse events Data presented at the American Academy of Ophthalmology 2022 Annual Meeting DURHAM, ...
Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
View the AAO presentation.
Atsena Therapeutics Announces Late-Breaker Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
Data from Phase I/II trial of ATSN-101 in patients with GUCY2D-associated Leber congenital amaurosis (LCA1) to be presented DURHAM, NC – Atsena Therapeutics, a clinical-stage gene ...
Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
World-class facility supports the company’s growth, and discovery and development of gene therapies for inherited retinal diseases DURHAM, NC – Atsena Therapeutics, a clinical-stage gene ...
Atsena Therapeutics Announces Presentations at ARVO 2022 Annual Meeting and ASGCT 25th Annual Meeting
Presentations to feature laterally spreading capsid for the treatment of X-linked retinoschisis and dual vector technology for the treatment of MYO7A-associated Usher syndrome DURHAM, NC ...
Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsids
Subretinal delivery of RS1 using AAV capsid that spreads laterally beyond the injection site overcomes challenges associated with intravitreal delivery DURHAM, NC – Atsena Therapeutics, a ...
Atsena Therapeutics Appoints Linda B. Couto, PhD, as Chief Scientific Officer
Dr. Couto strengthens leadership team with extensive AAV and ocular gene therapy expertise DURHAM, NC – Atsena Therapeutics, a clinical-stage gene therapy company focused on ...
Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors
DURHAM, NC – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today ...
Atsena Therapeutics Receives Orphan Drug Designation from the FDA for Novel Gene Therapy to Treat Genetic Eye Disease LCA1
Phase I/II clinical trial is ongoing in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D DURHAM, NC – Atsena Therapeutics, a clinical-stage ...
Atsena Therapeutics Appoints Kenji Fujita, MD, as Chief Medical Officer
Dr. Fujita brings extensive clinical development and regulatory strategy experience DURHAM, NC – Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing ...
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors Company expands board of directors and plans to build ...
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the ...
accessibility optionsAccessibility
Text Size
A
A